Search clinical trials for: Erbitux®

Total 14049 results

Bristol-Myers Squibb

Terminated

Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors

Head and Neck Cancer | Neoplasm Metastasis | Colorectal Cancer

United States, Canada
TyrNovo Ltd.

Active, not recruiting

A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer

Head and Neck Cancer | Squamous Cell Carcinoma of Head and Neck | Metastatic Solid Tumor | Colorectal Adenocarcinoma | Solid Tumor, Adult | Recurrent Solid Tumor

United States, Israel
Washington University School of Medicine
Novartis Pharmaceuticals

Completed

Pazopanib Plus Cetuximab for Incurable Head and Neck Squamous Cell Carcinoma (HNSCC) (HNSCC)

Squamous Cell Carcinoma of the Head and Neck

United States
Eli Lilly and Company

Completed

Study of IMC-A12, Alone or in Combination With Cetuximab, in Participants With Recurrent or Metastatic Squamous Cell Carcinoma (MSCC) of the Head and Neck

Head and Neck Cancer

United States
K-Group, Beta, Inc., a wholly owned subsidiary...
Pfizer

Recruiting

ZN-c3 in Adult Participants With Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

Spain, Australia, United States, Italy, Germany, Poland, Hungary
University of California, San Diego
Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma

Head and Neck Cancer | Head and Neck Neoplasms | Nasopharynx Cancer | Head and Neck Squamous Cell Carcinoma | Oropharynx Cancer | Oral Cavity Cancer | Larynx Cancer | HNSCC | Hypopharynx Cancer | Cutaneous Squamous Cell Carcinoma | Lip SCC | Sinonasal Carcinoma

United States
University of Zurich

Completed

A Phase II Study In Patients With Advanced Head And Neck Cancer Of Standard Chemoradiation And Add-On Cetuximab

Laryngeal Cancer | Hypopharyngeal Cancer | Oropharyngeal Cancer

Switzerland
King Faisal Specialist Hospital & Research Center

Completed

A Trial of Pre-Operative Chemoradiotherapy Using Capecitabine, Radiation & Cetuximab, in Rectal Cancer

Colon Rectal Cancer Duke Stage Stageval

Saudi Arabia
Groupe Oncologie Radiotherapie Tete et Cou

Completed

Trial of OTD70DERM® in Radio-dermatitis Induced by Radiotherapy-Erbitux® (GORTEC 2009-01)

Head and Neck Carcinoma

France
R-Pharm

Completed

A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer

Metastatic Pancreatic Cancer

United States
Nektar Therapeutics

Completed

Study of NKTR 255 in Combination With Cetuximab in Solid Tumors

Cervical Cancer | Colorectal Cancer | Head and Neck Squamous Cell Carcinoma | Anal Squamous Cell Carcinoma | Cutaneous Squamous Cell Carcinoma

United States
Merck KGaA, Darmstadt, Germany
Choice Pharma Taiwan

Completed

A Post Marketing Surveillance Study of Cetuximab in Patients With Squamous Cell Carcinoma of Head and Neck (SCCHN)

Carcinoma, Squamous Cell of Head and Neck

Taiwan
Martin Schuler, Prof. Dr. med.

Completed

Bi-weekly Cetuximab Combined With 5-fluorouracil/Leucovorin/Oxaliplatin (FOLFOX-6) in Metastatic Colorectal Cancer (CEBIFOX)

Metastatic Colorectal Cancer

Germany
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Terminated

Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE)

Colorectal Neoplasms

Spain, United States, France, Italy, Belgium, Czechia, United Kingdom, Russian Federation
Merck KGaA, Darmstadt, Germany

Completed

Cetuximab With Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck in Chinese Subjects (CHANCE)

Squamous Cell Carcinoma of the Head and Neck

China
Gilead Sciences
California Institute for Regenerative Medicine (CIRM)

Completed

Study of Magrolimab (Hu5F9-G4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer

Colorectal Cancer | Solid Tumor

United States
Eli Lilly and Company

Completed

Study Using IMC-A12 (Cixutumumab) With or Without Cetuximab in Participants With Metastatic Colorectal Cancer Who Have Failed a Treatment Regimen That Consisted of a Prior Anti-EGFR Therapy

Colorectal Cancer

United States
EMD Serono

Completed

EMD 1201081 in Combination With Cetuximab in Second-Line Cetuximab-Naïve Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Squamous Cell Carcinoma of the Head and Neck Cancer

Czech Republic, France, United Kingdom, Belgium, Hungary, United States, Poland, Slovakia
Bristol-Myers Squibb

Active, not recruiting

A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors

Advanced Solid Tumors

United States, France, Argentina, Australia, Belgium, Israel, Italy, Spain
University of Heidelberg Medical Center
iOMEDICO AG

Completed

Skin Changes in Head and Neck Cancer During Immuno-(Chemo-) And Radiotherapy With Erbitux® (HICARE) (HICARE)

Head and Neck Cancer

Germany
Merck KGaA, Darmstadt, Germany

Completed

A Korean Post-marketing Surveillance Study on Erbitux® in Patients With Metastatic Colorectal Cancer Refractory to Irinotecan-containing Treatment

Colorectal Neoplasms

Korea, Republic of
Sanofi
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)

Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | Oesophageal Adenocarcinoma | Oesophageal Squamous Cell Carcinoma

Korea, Republic of, Belgium, Italy, United States, Chile, China, France, Netherlands, Spain
Robert Ferris
Bristol-Myers Squibb

Completed

ERBITUX® Followed by Adjuvant Treatment With Chemoradiation and ERBITUX® for Locally Advanced Head and Neck Squamous Cell Carcinoma

Squamous Cell Carcinoma of the Head and Neck

United States
Sanofi
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With HNSCC (Master Protocol) (Pegathor Head and Neck 204)

Squamous Cell Carcinoma of Head and Neck

Spain, Italy, United States, Chile, France, Argentina, Canada, Germany, Korea, Republic of, Netherlands, Taiwan
Boehringer Ingelheim

Completed

Trial of Afatinib (BIBW 2992) + Cetuximab in Advanced Solid Tumours

Neoplasms

France, Spain
Washington University School of Medicine
Pfizer

Completed

PD 0332991 and Cetuximab in Patients With Incurable SCCHN

Carcinoma, Squamous Cell of Head and Neck

United States
University of Michigan Rogel Cancer Center

Terminated

Cetuximab and Radiation Therapy in Laryngeal Cancer Patients Who Have Responded to One Cycle of Chemotherapy (SPORE)

Cancer of Larynx

United States
Heinrich-Heine University, Duesseldorf

Completed

Adjuvant Cetuximab and Chemoradiation in Head and Neck Cancer (ACCRA-HN)

Head and Neck Cancer

Germany
Eli Lilly and Company
Bristol-Myers Squibb

Completed

Phase II Study in Patients With Recurrent Non-Small-Cell Lung Cancer

Non-Small-Cell Lung Cancer

United States
Merck Sharp & Dohme LLC
Eisai Inc.

Recruiting

Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)

Squamous Cell Carcinoma of Head and Neck

United States, Australia, Canada, Denmark, France, Israel, Korea, Republic of, Portugal, Romania, Spain, Taiwan, United Kingdom, Colombia, Brazil, Norway
Groupe Oncologie Radiotherapie Tete et Cou

Completed

Reirradiation and Erbitux in the HNSCC

Head and Neck Cancer Squamous Cell

France
Rambam Health Care Campus
Merck KGaA, Darmstadt, Germany

Completed

Does Acne Rash During Adolescence Predict Skin Reaction to Cetuximab

Colorectal Cancer Metastatic

Israel
Merck KGaA, Darmstadt, Germany
Merck, S.L., Spain

Completed

Cetuximab in Refractory Colorectal Cancer With K-RAS Mutated and Favorable FcγRIIa (CD32) Genotype (MUTEX)

Colorectal Neoplasms

Spain
Eli Lilly and Company

Completed

Study to Evaluate the Effect of Cetuximab on Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors

Advanced Cancer

Puerto Rico, United States
Merck KGaA, Darmstadt, Germany

Completed

Prospective, Post Marketing Surveillance Study On Erbitux® (Cetuximab) in Patients With Locally Advanced or Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck in Korea

Head and Neck Cancer

Korea, Republic of
Karolinska University Hospital

Unknown

Randomised Phase II, Cetuximab in Combination With 5FU and Cisplatin or Carboplatin Versus Cetuximab in Combination With Paclitaxel and Carboplatin for Treatment of Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck (CETMET)

Squamous Cell Carcinoma of the Head and Neck

Denmark, Sweden
Eli Lilly and Company
Bristol-Myers Squibb

Completed

A Study of Cetuximab in Patients Who Have Stage IV Colorectal Cancer

Colorectal Neoplasms

United States
Memorial Sloan Kettering Cancer Center
Eli Lilly and Company; National Comprehensive Cancer Network

Completed

Cetuximab at Either 500 or 750 mg/m2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell Cancer

Squamous Cell Cancer | Head and Neck

United States
Sorlandet Hospital HF
Merck KGaA, Darmstadt, Germany; Frontier Science & Technology Research Foundation...

Completed

Novel Treatment Option for Neuropathic Pain (NoTOPain)

Neuralgia | Complex Regional Pain Syndromes

Norway
Centre Hospitalier of Chartres
Hospital of Chartres- France

Completed

Study of Cetuximab in Squamous Cell Carcinoma of the Skin Expressing EGFR (CTXSCC)

Skin Diseases | Carcinoma, Squamous Cell

France
Merck KGaA, Darmstadt, Germany

Completed

A Trial to Determine the Safety and Anti-tumor Activity Profile of the Combination of Cetuximab and Concomitant Cisplatin Plus 5-Fluorouracil (5-FU) in Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma in Head and Neck (CHANGE)

Squamous Cell Carcinoma of the Head and Neck

China, Korea, Republic of
Merck KGaA, Darmstadt, Germany
Merck Ltd., India

Terminated

An Observational Study to Evaluate the Safety and Efficacy of Cetuximab in Combination With Platinum-based Chemotherapy in the First-line Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck

Carcinoma, Squamous Cell

India
Dana-Farber Cancer Institute
Bristol-Myers Squibb; Massachusetts General Hospital; Beth Israel Deaconess Medical...

Completed

Use of Cetuximab for Unresectable or Metastatic Esophageal and Gastric Cancer

Neoplasm Metastasis | Gastric Cancer | Esophageal Cancer

United States
Merck KGaA, Darmstadt, Germany

Withdrawn

A Post-marketing Surveillance Study on Erbitux in Combination With Platinum-based Chemotherapy in Metastatic/Recurrent Squamous Cell Cancer of the Head and Neck

Neoplasms, Squamous Cell
Merck KGaA, Darmstadt, Germany
Merck Ltd.

Terminated

An Observational Study of Erbitux® in Patients With Metastatic Colorectal Cancer (mCRC) Refractory to Irinotecan-containing Treatment

Colorectal Neoplasm

Korea, Republic of
ARCAGY/ GINECO GROUP

Terminated

Phase II Study , Association of Cisplatine Topotecan and Cetuximab in Patients Whith Late or in Progress Epithelial Cancer of the Cervix (ERBUS)

Cervix Cancer

France
Eli Lilly and Company
Bristol-Myers Squibb

Terminated

A Study in Patients With Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma

Ovarian Cancer

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer

Esophageal Cancer

United States
University of Pittsburgh
Bristol-Myers Squibb

Completed

Study of Cetuximab With Radiation Followed by Consolidation Chemotherapy for NSCLC

Non Small Cell Lung Cancer (NSCLC)

United States
Heidelberg University
Merck KGaA, Darmstadt, Germany; University Hospital Heidelberg; Dept. of Radiation...

Unknown

Adenoid Cystic Carcinoma, Erbitux, and Particle Therapy (ACCEPT)

Adenoid Cystic Carcinoma

Germany

Search clinical trials for: Erbitux®

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Korea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations